Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

- PMLiVE

FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer

The drug has been granted accelerated approval, and the companies have also released positive data on first-line treatment

- PMLiVE

AstraZeneca chooses Ireland for $360m manufacturing site

The next-generation facility will make small molecule active ingredients, future-proofing the company’s supply chain and boosting the Irish life sciences sector

- PMLiVE

Building the perfect behaviour-change buffet

By Kirsty Mead

IBD Registry wins Communiqué award for COVID-19 tool

The IBD Registry has won a coveted Communiqué award in recognition of its collaborative efforts in creating the COVID-19 IBD Risk Tool for people with inflammatory bowel disease (IBD).

Dovetail

Havas Life Medicom named Agency Digital Team and leads agency wins at PM Digital Awards

Wins included three gold, three silver and two bronze across multiple categories

Havas Life London

Roche Basel Switzerland

New data for Tecentriq in early-stage lung cancer

Roche’s PD-L1 blocker reduced the risk of disease recurrence and death for patients with stage 2-3a non-small cell lung cancer following surgery

- PMLiVE

Strong five-year survival data for Kisqali in breast cancer

Novartis’ Kisqali plus letrozole offers more than a year survival benefit for postmenopausal women with HR+/HER2 advanced breast cancer

- PMLiVE

A growth mindset frees us to believe that anything is possible

By Clare Bates

Queen’s Award Highlights Video

Innovative Trials was awarded the Queen's Award for Enterprise, and this video includes highlights of the ceremony days at the HQ in Letchworth.

Innovative Trials

- PMLiVE

Innovative Trials wins the Queen’s Award

Innovative Trials presented with Queen’s Award for international excellence in clinical trial patient recruitment

Innovative Trials

- PMLiVE

AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients

The drug tripled patient survival after three years in the longest-ever follow-up in extensive-stage small cell lung cancer

Biogen Idec building

Biogen’s Vumerity recommended by CHMP in MS

A thumbs up for Vumerity in the EU could ease the way for Biogen’s follow-up to Tecfidera in multiple sclerosis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links